Use este identificador para citar ou linkar para este item: http://repositorio.ufc.br/handle/riufc/62960
Tipo: Artigo de Periódico
Título: Kinase inhibition in relapsed/refractory leukemia and lymphoma settings: recent prospects into clinical investigations
Autor(es): Machado, Caio Bezerra
Pessoa, Flávia Melo Cunha de Pinho
Silva, Emerson Lucena da
Pantoja, Laudreísa da Costa
Ribeiro, Rodrigo Monteiro
Moraes Filho, Manoel Odorico de
Moraes, Maria Elisabete Amaral de
Montenegro, Raquel Carvalho
Burbano, Rommel Mário Rodriguez
Khayat, André Salim
Moreira-Nunes, Caroline Aquino
Palavras-chave: Neoplasias Hematológicas;Hematologic Neoplasms;Terapia de Alvo Molecular;Molecular Targeted Therapy
Data do documento: 2021
Instituição/Editor/Publicador: Pharmaceutics
Citação: MACHADO, Caio Bezerra et al. Kinase inhibition in relapsed/refractory leukemia and lymphoma settings: recent prospects into clinical investigations. Pharmaceutics, v. 13, n. 10, p. 1-26, oct. 2021. Disponível em: https://www.mdpi.com/1999-4923/13/10/1604. Acesso em: 13/12/2021.
Abstract: Cancer is still a major barrier to life expectancy increase worldwide, and hematologic neoplasms represent a relevant percentage of cancer incidence rates. Tumor dependence of continuous proliferative signals mediated through protein kinases overexpression instigated increased strategies of kinase inhibition in the oncologic practice over the last couple decades, and in this review, we focused our discussion on relevant clinical trials of the past five years that investigated kinase inhibitor (KI) usage in patients afflicted with relapsed/refractory (R/R) hematologic malignancies as well as in the pharmacological characteristics of available KIs and the dissertation about traditional chemotherapy treatment approaches and its hindrances. A trend towards investigations on KI usage for the treatment of chronic lymphoid leukemia and acute myeloid leukemia in R/R settings was observed, and it likely reflects the existence of already established treatment protocols for chronic myeloid leukemia and acute lymphoid leukemia patient cohorts. Overall, regimens of KI treatment are clinically manageable, and results are especially effective when allied with tumor genetic profiles, giving rise to encouraging future prospects of an era where chemotherapy-free treatment regimens are a reality for many oncologic patients.
URI: http://www.repositorio.ufc.br/handle/riufc/62960
ISSN: 1999-4923
Aparece nas coleções:PPGF - Artigos publicados em revistas científica

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2021_art_cbmachado.pdf1,51 MBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.